<p>紐約，紐約 --（Newsfile Corp. -2025 年 8 月 11 日）- 如果您在 <strong>諾和諾德公司</strong> 的投資中遭受損失，並希望瞭解根據聯邦證券法的潛在賠償，請點擊以下鏈接獲取更多信息：</p>
<p>https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=160780&amp;wire=5&amp;utm_campaign=22</p>
<p>或通過電子郵件聯繫 Joseph E. Levi 律師，郵箱為 jlevi@levikorsinsky.com，或撥打（212）363-7500 與我們經驗豐富的股東倡導團隊聯繫。</p>
<p><strong>訴訟：</strong> 針對諾和諾德公司提起了一項集體訴訟，旨在為在 2025 年 5 月 7 日至 2025 年 7 月 28 日期間受到證券欺詐影響的股東追回損失。</p>
<p><strong>案件詳情：</strong> 根據投訴，被告向投資者提供了極為積極的聲明，同時傳播了實質性虛假和誤導性陳述和/或隱瞞了有關諾和諾德增長潛力真實狀況的重大不利事實；特別是，其聲稱的利用複合市場的潛力大大低估了個性化例外對複合 GLP-1 排除的潛在影響，並高估了這些患者轉向諾和諾德品牌替代品的可能性，進一步高估了潛在的 GLP-1 市場或諾和諾德進入這些市場以實現持續增長的能力。</p>
<p>2025 年 7 月 29 日，諾和諾德宣佈在報告 2025 財年第二季度業績之前下調銷售和利潤預期。公司將下調指導歸因於&#34;對 2025 年下半年 Wegovy 和 Ozempic 的增長預期降低&#34;，原因是&#34;複合 GLP-1 的持續使用、市場擴展慢於預期和競爭。&#34;</p>
<p>在此消息發佈後，諾和諾德的普通股價格大幅下跌。從 2025 年 7 月 28 日的收盤市場價格每股 69.00 美元，諾和諾德的股價在 2025 年 7 月 29 日跌至每股 53.94 美元，單日下降約 21.83%。</p>
<p><strong>接下來會怎樣？</strong> 如果您在相關時間段內在諾和諾德股票中遭受損失——即使您仍持有股票——請訪問 https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=160780&amp;wire=5&amp;utm_campaign=22 瞭解您尋求賠償的權利。<strong>參與沒有費用或義務。</strong></p>
<p><strong>為什麼選擇 Levi &amp; Korsinsky：</strong> 在過去 20 年中，Levi &amp; Korsinsky LLP 已建立為一家全國知名的證券訴訟公司，為受害股東爭取了數億美元，並在高風險案件中贏得了良好的記錄。該公司在複雜證券訴訟方面擁有豐富的經驗，並擁有超過 70 名員工為客户服務。連續七年，Levi &amp; Korsinsky 在 ISS 證券集體訴訟服務的前 50 名報告中被評為美國頂級證券訴訟公司之一。律師廣告。以往的結果並不保證類似的結果。</p>
<p><strong>聯繫方式：</strong></p>
<p>Levi &amp; Korsinsky, LLP</p>
<p>Joseph E. Levi, Esq.</p>
<p>Ed Korsinsky, Esq.</p>
<p>33 Whitehall Street, 17th Floor</p>
<p>紐約，NY 10004</p>
<p>jlevi@levikorsinsky.com</p>
<p>電話：（212）363-7500</p>
<p>傳真：（212）363-7171</p>
<p>https://zlk.com/</p>
<p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/261999</p>

諾和諾德公司

<p>針對諾和諾德公司（Novo Nordisk A/S）提起了一項集體訴訟，指控其在 2025 年 5 月 7 日至 2025 年 7 月 28 日期間對股東進行證券欺詐。訴訟稱，該公司誤導投資者關於其增長潛力的信息，導致在 2025 年 7 月 29 日宣佈負面銷售前景後，股價大幅下跌約 21.83%。遭受損失的股東被鼓勵在 2025 年 9 月 30 日之前聯繫 Levi & Korsinsky LLP，以尋求潛在的賠償選項</p>

<p>New York, New York--(Newsfile Corp. - August 11, 2025) - If you suffered a loss on your <strong>Novo Nordisk A/S</strong> investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:</p>
<div class="lb-trans"><p>紐約，紐約 --（Newsfile Corp. -2025 年 8 月 11 日）- 如果您在 <strong>諾和諾德公司</strong> 的投資中遭受損失，並希望瞭解根據聯邦證券法的潛在賠償，請點擊以下鏈接獲取更多信息：</p>
</div><p>https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=160780&amp;wire=5&amp;utm_campaign=22</p>
<div class="lb-trans"><p>https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=160780&amp;wire=5&amp;utm_campaign=22</p>
</div><p>or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.</p>
<div class="lb-trans"><p>或通過電子郵件聯繫 Joseph E. Levi 律師，郵箱為 jlevi@levikorsinsky.com，或撥打（212）363-7500 與我們經驗豐富的股東倡導團隊聯繫。</p>
</div><p><strong>THE LAWSUIT:</strong> A class action securities lawsuit was filed against Novo Nordisk A/S that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between May 7, 2025 and July 28, 2025.</p>
<div class="lb-trans"><p><strong>訴訟：</strong> 針對諾和諾德公司提起了一項集體訴訟，旨在為在 2025 年 5 月 7 日至 2025 年 7 月 28 日期間受到證券欺詐影響的股東追回損失。</p>
</div><p><strong>CASE DETAILS:</strong> According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo's growth potential; notably, that its asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo's branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo's capability to penetrate said markets to achieve continued growth.</p>
<div class="lb-trans"><p><strong>案件詳情：</strong> 根據投訴，被告向投資者提供了極為積極的聲明，同時傳播了實質性虛假和誤導性陳述和/或隱瞞了有關諾和諾德增長潛力真實狀況的重大不利事實；特別是，其聲稱的利用複合市場的潛力大大低估了個性化例外對複合 GLP-1 排除的潛在影響，並高估了這些患者轉向諾和諾德品牌替代品的可能性，進一步高估了潛在的 GLP-1 市場或諾和諾德進入這些市場以實現持續增長的能力。</p>
</div><p>On July 29, 2025, Novo announced it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025. The Company attributed the guide down on &#34;lowered growth expectations for the second half of 2025&#34; for both Wegovy and Ozempic due to &#34;the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition.&#34;</p>
<div class="lb-trans"><p>2025 年 7 月 29 日，諾和諾德宣佈在報告 2025 財年第二季度業績之前下調銷售和利潤預期。公司將下調指導歸因於&#34;對 2025 年下半年 Wegovy 和 Ozempic 的增長預期降低&#34;，原因是&#34;複合 GLP-1 的持續使用、市場擴展慢於預期和競爭。&#34;</p>
</div><p>Following this news, the price of Novo's common stock declined dramatically. From a closing market price of $69.00 per share on July 28, 2025, Novo's stock price fell to $53.94 per share on July 29, 2025, a decline of about 21.83% in the span of just a single day.</p>
<div class="lb-trans"><p>在此消息發佈後，諾和諾德的普通股價格大幅下跌。從 2025 年 7 月 28 日的收盤市場價格每股 69.00 美元，諾和諾德的股價在 2025 年 7 月 29 日跌至每股 53.94 美元，單日下降約 21.83%。</p>
</div><p><strong>WHAT'S NEXT?</strong> If you suffered a loss in Novo stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=160780&amp;wire=5&amp;utm_campaign=22 to learn about your rights to seek a recovery. <strong>There is no cost or obligation to participate.</strong></p>
<div class="lb-trans"><p><strong>接下來會怎樣？</strong> 如果您在相關時間段內在諾和諾德股票中遭受損失——即使您仍持有股票——請訪問 https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=160780&amp;wire=5&amp;utm_campaign=22 瞭解您尋求賠償的權利。<strong>參與沒有費用或義務。</strong></p>
</div><p><strong>WHY LEVI &amp; KORSINSKY:</strong> Over the past 20 years, Levi &amp; Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p><strong>為什麼選擇 Levi &amp; Korsinsky：</strong> 在過去 20 年中，Levi &amp; Korsinsky LLP 已建立為一家全國知名的證券訴訟公司，為受害股東爭取了數億美元，並在高風險案件中贏得了良好的記錄。該公司在複雜證券訴訟方面擁有豐富的經驗，並擁有超過 70 名員工為客户服務。連續七年，Levi &amp; Korsinsky 在 ISS 證券集體訴訟服務的前 50 名報告中被評為美國頂級證券訴訟公司之一。律師廣告。以往的結果並不保證類似的結果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP</p>
</div><p>Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.</p>
</div><p>Ed Korsinsky, Esq.</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.</p>
</div><p>33 Whitehall Street, 17th Floor</p>
<div class="lb-trans"><p>33 Whitehall Street, 17th Floor</p>
</div><p>New York, NY 10004</p>
<div class="lb-trans"><p>紐約，NY 10004</p>
</div><p>jlevi@levikorsinsky.com</p>
<div class="lb-trans"><p>jlevi@levikorsinsky.com</p>
</div><p>Tel: (212) 363-7500</p>
<div class="lb-trans"><p>電話：（212）363-7500</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>傳真：（212）363-7171</p>
</div><p>https://zlk.com/</p>
<div class="lb-trans"><p>https://zlk.com/</p>
</div><p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261999</p>
<div class="lb-trans"><p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/261999</p>
</div>

在諾和諾德公司（NVO）上虧損的投資者被敦促在2025年9月30日前加入集體訴訟 - 請聯繫 Levi & Korsinsky